초록 ▼

The present invention relates to tasty, ready-to-eat, nutritional foods that offer an alternative to appealing but unhealthy foods. More particularly, tasty, ready-to-eat, nutritional foods that provide a balanced mix of amino acids, fat, and carbohydrates are disclosed. Processes for making, and me

The present invention relates to tasty, ready-to-eat, nutritional foods that offer an alternative to appealing but unhealthy foods. More particularly, tasty, ready-to-eat, nutritional foods that provide a balanced mix of amino acids, fat, and carbohydrates are disclosed. Processes for making, and methods of using said tasty, ready-to-eat, nutritional foods are also disclosed. The nutritious foods of the present invention are formulated and processed such that they resolve the dilemma that consumers have always been faced with--healthy eating or enjoying what they eat.

대표청구항 ▼

The present invention relates to tasty, ready-to-eat, nutritional foods that offer an alternative to appealing but unhealthy foods. More particularly, tasty, ready-to-eat, nutritional foods that provide a balanced mix of amino acids, fat, and carbohydrates are disclosed. Processes for making, and me

The present invention relates to tasty, ready-to-eat, nutritional foods that offer an alternative to appealing but unhealthy foods. More particularly, tasty, ready-to-eat, nutritional foods that provide a balanced mix of amino acids, fat, and carbohydrates are disclosed. Processes for making, and methods of using said tasty, ready-to-eat, nutritional foods are also disclosed. The nutritious foods of the present invention are formulated and processed such that they resolve the dilemma that consumers have always been faced with--healthy eating or enjoying what they eat. e in soft capsule dosage forms comprising: a) loratadine and derivatives thereof in a pharmaceutically effective amount; and b) a solvent system comprising a mixture of medium chain fatty acids; wherein the mixture of medium chain fatty acids is present in an amount of about 89.0% by weight or less of the total composition; and wherein said loratadine and derivatives thereof is present in an amount of about 6.3% by weight of the total composition. 3. A pharmaceutical composition for use in soft capsule dosage forms comprising: a) loratadine and derivatives thereof in a pharmaceutically effective amount; and b) a solvent system comprising a mixture of medium chain fatty acids; and further comprising a dispersant; and wherein said loratadine and derivatives thereof is present in an amount of about 6.3% by weight of the total composition. 4. The composition of claim 1 wherein said loratadine derivatives are decarbalkoxylated forms of loratadine. 5. The composition of claim 4 wherein the decarbalkoxylated loratadine derivative is descarboethoxyloratadine. 6. The composition of claim 1 wherein said loratadine and derivatives thereof is present in an amount of less than 6.3% of the total composition. 7. The composition of claim 1 wherein said mixture of medium chain fatty acids is a mixture of mono- and diglycerides of medium chain fatty acids. 8. The composition of claim 7 wherein said mixture of mono- and diglycerides of medium chain fatty acids comprises a mixture of caprylic acid and capric acid. 9. The composition of claim 2 wherein the mixture of medium chain fatty acids is present in an amount of from about 89.0% to about 80.0% by weight of the total composition. 10. The composition of claim 3 wherein the dispersant is present in an amount of about 8.0% by weight or less of the total fill composition. 11. The composition of claim 10 wherein the dispersant is present in an amount ranging from about 7.5% to about 7.0% by weight of the total composition. 12. The composition of claim 10 wherein the dispersant comprises povidone and polyoxyethylene sorbitan fatty acid ester. 13. The composition of claim 12 wherein the povidone to polyoxyethylene sorbitan fatty acid ester ratio is from about 10:1 to about 15:1. 14. The composition of claim 13 wherein the ratio of povidone to polyoxyethylene sorbitan fatty acid ester is about 10:1. 15. The composition of claim 1 wherein said soft capsule dosage form is a soft gelatin capsule. 16. A pharmaceutical composition for use in soft capsule dosage forms consisting essentially of: a) loratadine and derivatives thereof present in an amount of about 6.3% by weight of the total composition; b) mono- and di-glycerides of medium chain fatty acids present in an amount of about 87% by weight of the total composition; c) povidone present in an amount of about 6.3% by weight of the total composition; and d) polyoxyethylene sorbitan fatty acid ester present in an amount of about 0.8% by weight of the total composition. 17. A pharmaceutical composition for use in soft gelatin dosage forms consisting essentially of: a) decarboalkoxylated loratadine derivative in a pharmaceutically effective amount; b) a mixture of mono- and d-glycerides of medium chain fatty acids comprising a mixture of caprylic and capric acid; c) povidone; and d) polyoxyethylene sorbitan fatty acid esters; wherein said loratadine derivative is present in an amount of about 6.3% by weight of the total composition. 18. The composition of claim 17 wherein the decarbalkoxylated loratadine derivative is descarboethoxyloratadine. 19. A soft capsule dosage form comprising a fill composition consisting essentially of: a) loratadine and derivatives thereof in a pharmaceutically effective amount; b) a mixture of mono- and diglycerides of medium chain fatty acids; c) povidone; d) polyoxyethylene sorbitan fatty acid ester; and wherein said loratadine and derivatives thereof is present in an amount of about 6.3% by weight of the total composition, and wherein said soft capsule has a capsule size of 5 minim or less. 20. The soft capsule of claim 19 wherein the capsule size is a 3 minim oval.